RESUMEN
The BRAF V600E mutation and BRAF inhibitor responsiveness characterize â¼50% of patients with the non-Langerhans cell histiocytosis (non-LCH) Erdheim-Chester disease (ECD). We interrogated the non-LCH molecular landscape [ECD, n = 35; Rosai-Dorfman disease (RDD), n = 3; mixed ECD/RDD, n = 1] using BRAF V600E PCR and/or next-generation sequencing [tissue and cell-free DNA (cfDNA) of plasma and/or urine]. Of 34 evaluable patients, 17 (50%) had the BRAF V600E mutation. Of 31 patients evaluable for non-BRAF V600E alterations, 18 (58%) had ≥1 alteration and 12 putative non-BRAF V600E MAPK pathway alterations: atypical BRAF mutation; GNAS, MAP2K1, MAP2K2, NF1, and RAS mutations; RAF1 or ERBB2 amplifications; LMNA-NTRK1 (TRK inhibitor-sensitive) and CAPZA2-BRAF fusions. Four patients had JAK2, MPL ASXL1, U2AF1 alterations, which can correlate with myeloid neoplasms, a known ECD predisposition, and one developed myelofibrosis 13 months after cfDNA testing. Therefore, our multimodal comprehensive genomics reveals clinically relevant alterations and suggests that MAPK activation is a hallmark of non-LCH.
Asunto(s)
Ácidos Nucleicos Libres de Células/genética , Enfermedad de Erdheim-Chester/sangre , Enfermedad de Erdheim-Chester/patología , Genómica/métodos , Histiocitosis Sinusal/sangre , Histiocitosis Sinusal/patología , Adolescente , Adulto , Anciano , Detección Precoz del Cáncer/métodos , Enfermedad de Erdheim-Chester/orina , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento , Histiocitosis Sinusal/orina , Humanos , Leucemia Mieloide/diagnóstico , Masculino , Persona de Mediana Edad , Proteínas Quinasas Activadas por Mitógenos/genética , Mutación , Reacción en Cadena de la Polimerasa , Proteínas Proto-Oncogénicas B-raf/genética , Adulto JovenRESUMEN
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can respond to BRAF inhibitors. Unfortunately, the lack of adequate archival tissue often precludes BRAF testing. We hypothesized that cell-free DNA (cfDNA) from plasma or urine can offer an alternative source of biologic material for testing. We tested for BRAF V600E mutation in cfDNA from the plasma and urine of 6 ECD patients. In patients with available archival tissue, the result of BRAF mutation analysis was concordant with plasma and urine cfDNA results in all 3 patients (100% agreement, kappa 1.00). In all 6 patients, BRAF mutation analysis of plasma and urine cfDNA was concordant in 5 of 6 patients (83% agreement, kappa 0.67). Testing for BRAF V600E mutation in plasma and urine cfDNA should be further investigated as an alternative to archival tissue mutation analysis.
